References
- Benet LZ, Hoener BA. (2002). Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115–21
- Brée F, Houin G, Barré J, et al. (1986). Pharmacokinetics of intravenously administered 125I-labelled human α1-acid glycoprotein. Clin Pharmacokinet 11:336–42
- Colombo S, Buclin T, Decosterd LA, et al. (2006). Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin Pharmacol Ther 80:307–18
- Guyton AC, Lindsey AW. (1959). Effect of elevated left atrial pressure and decreased plasma protein concentration on the development of pulmonary edema. Circ Res 7:649–57
- Heuberger J, Schmidt S, Derendorf H. (2013). When is protein binding important? J Pharm Sci 102:3458–67
- Kitamura K, Takegami S, Tanaka R, et al. (2013). Effect of long-chain fatty acids on the binding of triflupromazine to human serum albumin: a spectrophotometric study. Sci Pharm 82:233–45
- Kremer JM, Wilting J, Janssen LH. (1988). Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40:1–47
- Nicholson JP, Wolmarans MR, Park GR. (2000). The role of albumin in critical illness. Brit J Anaest 85:599–610
- Øie S, Tozer TN. (1979). Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 68:1203–5
- Roberts JA, Pea F, Lipman J. (2013). The clinical relevance of plasma protein binding changes. Clin Pharmacokinet 52:1–8
- Roca L, Calligaris S, Wennberg RP, et al. (2006). Factors affecting the binding of bilirubin to serum albumins: validation and application of the peroxidase method. Pediatr Res 60:724–8
- Sparreboom A, Nooter K, Loos WJ, Verweij J. (2001). The (ir)relevance of plasma protein binding of anticancer drugs. Neth J Med 59:196–207
- Svennebring A. (2014a). Visualization of plasma and tissue binding using dose fractions parameter. Drug Dev Res 75:425–37
- Svennebring AM. (2014b). Investigation of the prerequisites for the optimization of specific plasma protein binding as a strategy for the reduction of first-pass hepatic metabolism. Xenobiotica 3:1–16
- Waters NJ, Lombardo F. (2010). Use of the Oie-Tozer model in understanding mechanisms and determinants of drug distribution. Drug Metab Dispos 38:1159–65